Sandramycin is a cyclic depsipeptide antibiotic that was first isolated from cultured broth of a Nocardioides sp [1].
Sandramycin is an antitumor antibiotic. Sandramycin was closely related to the cyclic depsipeptides luzopeptins A, B, C and D. Sandramycin exhibited strong inhibition to the Gram-positive organisms Bacillus subtilis, Staphylococcus aureus and Streptococcusfaecalis. Its antimicrobial activity paralleled that which was observed for echinomycin and luzopeptin A [1]. Sandramycin was also a bifunctional DNA intercalator that strongly binds DNA and forms crosslinks between DNA molecules [2].
In transplantable mouse leukemia P388, Sandramycin was moderately active with values comparable to those for luzopeptin A. Injection of 2 mg/kg showed the best increase in life span over the controls (61%) [1].
References:
[1]. Matson JA, Bush JA. Sandramycin, a novel antitumor antibiotic produced by a Nocardioides sp. Production, isolation, characterization and biological properties. J Antibiot (Tokyo). 1989 Dec;42(12):1763-7.
[2]. Boger DL, Saionz KW. DNA binding properties of key sandramycin analogues: systematic examination of the intercalation chromophore. Bioorg Med Chem. 1999 Feb;7(2):315-21.